News & Events

ABZENA ACQUIRED BY ASTRO BIDCO LIMITED, A NEW COMPANY WHOLLY-OWNED BY THE WCAS FUND IN NEW YORK

17/08/2018

The Big Apple has taken another bite out of Cambridge UK biotech with a near-$44 million acquisition of Abzena by a newly-formed New York enterprise.

ACCELERATE@BABRAHAM START-UP COMPETITION: WINNERS ANNOUNCED

13/07/2018

Five science start-ups have been awarded £20k and access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham.

PREDICTIMMUNE APPOINTS NEW CEO

02/07/2018

PredictImmune, a developer of pioneering prognostic products for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the appointment of Paul Kinnon as its new Chief Executive Officer.

HOW UK LIFE SCIENCES WILL TRANSFORM OUR LIVES

26/06/2018

Taylor Vinters is an international law firm supporting the businesses which drive the innovation economy, and the entrepreneurs and private wealth that underpin them.

SHIONOGI INVESTS IN NEMESIS TECHNOLOGY

19/06/2018

Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience. Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M.

THE BABRAHAM RESEARCH CAMPUS LAUNCHES START-UP COMPETITION FOR THE CHANCE TO ACCESS ITS LIFE SCIENCE BIO-INCUBATOR, ACCELERATE@BABRAHAM

29/05/2018

Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities and much more...

PREDICTIMMUNE JOIN THE BABRAHAM RESEARCH CAMPUS COMMUNITY

14/05/2018

Developer of pioneering tools for guiding treatment options in immune-mediated inflammatory diseases choose Babraham Research Campus as permanent base within the Cambridge Cluster.

PredictImmune secures £4.3m investment from Wellcome Trust to evaluate the clinical utility of its prognostic test in Crohn’s disease

30/04/2018

PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.

IMPERIAL COLLEGE THINKSPACE FILLS SPACE AT THE BABRAHAM RESEARCH CAMPUS

17/04/2018

Imperial College ThinkSpace has welcomed two companies, Abzena plc and Bicycle Therapeutics Ltd, into its new 49,500 sqft building (Building 900) at the Babraham Research Campus near Cambridge.

THE BABRAHAM RESEARCH CAMPUS APPOINTS DR KAROLINA ZAPADKA TO LEAD ACCELERATE@BABRAHAM

19/03/2018

The Babraham Research Campus is delighted to announce the appointment of Dr Karolina Zapadka as Business Acceleration Manager for the Babraham Research Campus’ bio-incubator and life science accelerator, Accelerate@Babraham.

Registration now open for Babraham Investor Conference (BIC) 2018

16/03/2018

Our highly successful annual Investor Conference for investors focusing on early-stage and scale-up life science and med-tech companies seeking Seed to Series C funding returns on the 22nd May. Find out more and register by clicking here.

DEREK JONES JOINS THE REGION'S LIFE SCIENCE & HEALTHCARE MEMBERSHIP ORGANISATION

07/03/2018

One Nucleus is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

25/01/2018

Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes (the ‘accelerator’).

Abzena takes on new facilities in Cambridge, UK and San Diego

05/01/2018

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.

BBT 'Technology Development Laboratory' (TDL) moves to Abzena

05/01/2018

Abzena plc has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

04/01/2018

Bicycle Therapeutics announced today that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.

BioMed@Babraham Partnership Launch

20/12/2017

In October 2017, we were delighted to launch our partnership with BioMed Realty. This collaboration will see a new 108,000 square foot scale-up research space for growing bioscience-based companies built on site. Watch the launch video to find out more.

NOVOGENE ESTABLISHES FIRST EUROPEAN GENOMIC SEQUENCING CENTER AT THE BABRAHAM RESEARCH CAMPUS

21/05/2018

Novogene, a leading global provider of genomic services and solutions, today announced its first genomic sequencing center in Europe.

Biosceptre welcomes Tuspark S & T into its Series A fund raising round

14/12/2017

Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X_7.

Bicycle Therapeutics & Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

Bicycle Therapeutics and Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

06/12/2017

Bicycle Therapeutics and Cancer Research UK today announced that their collaboration has secured a prestigious Scrip Award, winning 2017’s Best Partnership Alliance.

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore

15/12/2017

Sixth Element Capital LLP (6EC), a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund, announces a £3 million investment in NeoPhore Ltd, a spin out from Cambridge, UK based PhoreMost Ltd.

MRC spin out Bicycle Therapeutics announces partnership with AstraZeneca in $1bn deal

15/12/2017

In 2016, Bicycle Therapeutics - a MRC spin out company - entered into a collaboration with AstraZeneca potentially worth $1bn.

Crescendo Biologics Shortlisted for ‘Licensing Deal of The Year’

01/11/2017

Crescendo Biologics is pleased to announce that it has been shortlisted for ‘Licensing Deal of the Year’ at the Scrip Awards 2017.

Sphere Fluidics' Cyto-Mine wins major European Product Innovation award

01/11/2017

Sphere Fluidics’ proprietary Cyto-Mine^® platform can perform multiple tasks in a single compact and portable system, reducing equipment costs and lab space.

Babraham Research Campus announces new life science development

26/10/2017

New project in grounds of the Babraham Research Campus will enhance Cambridge’s global position in life sciences community.

The only meeting checklist you’ll ever need

19/10/2017

The events team at Babraham Research Campus has many years of event management experience between them, here they share their knowledge to ensure your next meeting is a success.

How to use social media to make your next event memorable

How to use social media to make your next event really memorable

26/09/2017

We’ve all attended lots of events – training courses, team meetings, conferences – but some will stand out in your mind more than others. Why is this?

Solving the Problem of Scale Up - Babraham Panel Discussion

12/07/2017

See highlights of a panel discussion held in The Cambridge Building, which gathered senior key opinion leaders together to discuss the BioMed@Babraham development as well as the life science sector more broadly.

Babraham Research Campus Bennet Building

23/04/2017

The construction of the Bennet Building at the Babraham Research campus is discussed together with the role of the campus and BBSRC in innovation.

Cambridge Life Sciences

01/04/2017

Babraham Campus CEO Derek Jones leads us through a short history of monoclonal antibody research in the Cambridge life science cluster and asks what the next big thing will be in this area of exciting medical technology.

Bicycle Therapeutics Strengthens Senior Management Team

26/09/2017

Bicycle Therapeutics Strengthens Senior Management Team With Appointment of Maria Koehler, M.D., Ph.D., as Chief Medical Officer.

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

20/09/2017

Evelyn Warner, Editor of LaBiotech.eu, a leading digital media publisher covering the European Biotech industry interviews Derek Jones, Chief Executive of Babraham Bioscience Technologies (BBT) to talk about strategies for biotech startups.

How to find the perfect venue for your next meeting

20/09/2017

Behind every successful meeting, lies the perfect venue. This can often be overlooked while you’re focussing on the smaller details of the day. If you’re responsible for coordinating your organisation’s next conference, or seminar, choosing the right space will be crucial to it's success.

Support for - The UK Life Science Strategy - ‘Making the UK the best place for life sciences businesses to grow’

30/08/2017

As part of the UK’s £64B life sciences sector Babraham Bioscience Technologies, (BBT), welcomes the publication of Prof. Sir John Bell’s Life Science Industrial Strategy to the UK Government.

CEGX and NuGEN Technologies Sign Partnership Agreement

15/08/2017

Cambridge Epigenetix (CEGX) and NuGEN Technologies, today announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.

Bicycle Therapeutics Expands Leadership Team

01/08/2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the appointment of Lee Kalowski as Chief Financial Officer.

Campus